Glaukos Corporation (GKOS)
NYSE: GKOS · Real-Time Price · USD
121.48
+0.61 (0.50%)
Apr 24, 2026, 4:00 PM EDT - Market closed
Glaukos Revenue
In the year 2025, Glaukos had annual revenue of $507.44M with 32.33% growth. Glaukos had revenue of $143.12M in the quarter ending December 31, 2025, with 35.66% growth.
Revenue (ttm)
$507.44M
Revenue Growth
+32.33%
P/S Ratio
14.00
Revenue / Employee
$463,841
Employees
1,094
Market Cap
7.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 507.44M | 123.96M | 32.33% |
| Dec 31, 2024 | 383.48M | 68.77M | 21.85% |
| Dec 31, 2023 | 314.71M | 31.85M | 11.26% |
| Dec 31, 2022 | 282.86M | -11.15M | -3.79% |
| Dec 31, 2021 | 294.01M | 69.05M | 30.70% |
| Dec 31, 2020 | 224.96M | -12.03M | -5.07% |
| Dec 31, 2019 | 236.98M | 55.71M | 30.73% |
| Dec 31, 2018 | 181.28M | 22.02M | 13.83% |
| Dec 31, 2017 | 159.25M | 44.86M | 39.21% |
| Dec 31, 2016 | 114.40M | 42.70M | 59.55% |
| Dec 31, 2015 | 71.70M | 26.11M | 57.28% |
| Dec 31, 2014 | 45.59M | 24.64M | 117.64% |
| Dec 31, 2013 | 20.95M | 18.52M | 762.33% |
| Dec 31, 2012 | 2.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Smith & Nephew | 6.16B |
| Bruker | 3.44B |
| Globus Medical | 2.94B |
| Insulet | 2.71B |
| Bio-Rad Laboratories | 2.58B |
| Bio-Rad Laboratories | 2.58B |
| Masimo | 1.53B |
| Penumbra | 1.40B |
GKOS News
- 9 days ago - Glaukos Announces the Release of its 2025 Sustainability Report - Business Wire
- 10 days ago - Glaukos Receives Permanent J-code for Epioxa™ - Business Wire
- 17 days ago - Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29 - Business Wire
- 19 days ago - Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting - Business Wire
- 5 weeks ago - Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care - Business Wire
- 2 months ago - These Analysts Boost Their Forecasts On Glaukos Following Q4 Results - Benzinga
- 2 months ago - Glaukos Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results - Business Wire